AKG Metabolite Pathway Slows Stem Cell Aging via Newly Identified Protein Axis
Scientists pinpoint the AKG-IDH1-RPS23 axis as a key regulator of stem cell senescence, opening new doors for anti-aging metabolic therapies.
Summary
Researchers identified how the metabolite alpha-ketoglutaric acid (AKG) slows aging in mesenchymal stem cells. During senescence, the enzyme IDH1 declines, reducing AKG production and accelerating aging. Restoring AKG—either exogenously or via IDH1 overexpression—activates OGFOD1-mediated hydroxylation of ribosomal protein RPS23, improving protein quality control and translation accuracy. The natural flavonoid scutellarin was identified as an IDH1 agonist that boosts AKG levels. In aged mice, scutellarin improved cognitive function, reduced osteoporosis and skin aging, and suppressed the pro-inflammatory senescence-associated secretory phenotype (SASP). These findings map a druggable metabolic pathway linking cellular energy metabolism to stem cell longevity.
Detailed Summary
Alpha-ketoglutaric acid (AKG) is a well-known longevity-associated metabolite tied to the tricarboxylic acid (TCA) cycle, but the precise molecular targets mediating its anti-aging effects have remained elusive. This study tackles that gap by investigating how AKG delays senescence in mesenchymal stem cells (MSCs), a cell type critical to tissue repair and regeneration throughout life.
The researchers found that isocitrate dehydrogenase 1 (IDH1), the enzyme responsible for producing AKG, is progressively downregulated during cellular senescence. This decline lowers intracellular AKG levels, creating a feedback loop that accelerates aging. Supplementing cells with exogenous AKG or overexpressing IDH1 restored AKG concentrations and delayed senescence markers.
Mechanistically, AKG acts by stabilizing the interaction between OGFOD1—a 2-oxoglutarate and Fe(II)-dependent oxygenase—and the ribosomal protein RPS23. This stabilization promotes hydroxylation of RPS23 at proline 62, which enhances translational accuracy, reduces misfolded protein accumulation, and preserves proteostasis without compromising overall protein synthesis rates.
The team also screened for natural compounds that could activate IDH1 and identified scutellarin, a flavonoid found in traditional Chinese herbal medicine. In aged mouse models, scutellarin elevated AKG levels and produced measurable improvements across multiple aging phenotypes: better cognitive performance, reduced bone loss, improved skin integrity, and lower SASP cytokine output.
These findings are significant because they define a specific, druggable metabolic axis—AKG-IDH1-RPS23—linking TCA cycle activity to stem cell proteostasis and systemic aging. Caveats include reliance on mouse models for in vivo validation and the abstract-only nature of available data, meaning full mechanistic details and dosing parameters require review of the complete manuscript.
Key Findings
- IDH1 expression declines during senescence, reducing AKG production and accelerating MSC aging.
- AKG stabilizes the OGFOD1-RPS23 complex, boosting translational accuracy and proteostasis.
- The flavonoid scutellarin acts as an IDH1 agonist, elevating AKG to delay stem cell senescence.
- Scutellarin improved cognition, reduced osteoporosis, and suppressed SASP in aged mice.
- The AKG-IDH1-RPS23 axis is identified as a novel regulator of stem cell and systemic aging.
Methodology
Study used human mesenchymal stem cells with senescence models, combined with IDH1 overexpression and exogenous AKG supplementation to dissect mechanism. In vivo validation was performed in aged mice treated with scutellarin, assessing cognitive, skeletal, skin, and inflammatory aging endpoints. Protein interaction and hydroxylation analyses were used to characterize the OGFOD1-RPS23 mechanistic pathway.
Study Limitations
Full study details are unavailable as only the abstract was accessible, limiting assessment of statistical rigor and experimental depth. In vivo findings are based on mouse models, and translation to human aging physiology requires clinical validation. Scutellarin dosing, bioavailability, and long-term safety in humans remain to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.